Ketesse (Dexketoprofen)

Dexketoprofen works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins that mediate inflammation, pain, and fever. The lowered prostaglandin levels diminish peripheral sensitisation and provide rapid analgesic and anti‑inflammatory effects.

The specific dose of Ketesse is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare providers typically select an appropriate intramuscular or intravenous dose, and the exact regimen should follow the prescriber’s instructions and local guidelines.

Safety data for dexketoprofen in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Ketesse, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Ketesse (dexketoprofen) is the S‑enantiomer of ketoprofen, offering a faster onset of analgesia and potentially lower gastrointestinal irritation compared with non‑selective NSAIDs such as ibuprofen or diclofenac. Compared with ketorolac, another injectable NSAID, dexketoprofen provides comparable pain relief with a slightly different safety profile, especially regarding renal and cardiovascular risk.

Ketesse must be stored at 2 °C to 8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if the container is damaged or the solution appears discoloured.

Ketesse is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration should be performed by a qualified healthcare professional using aseptic technique, with the dose prepared according to the prescriber’s order and the product’s labeling.

Serious risks include gastrointestinal bleeding or ulceration, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, cardiovascular events like myocardial infarction or stroke, acute renal failure, and hepatic injury. Patients should be monitored closely for signs of these conditions, especially if they have pre‑existing risk factors.

Ketesse is contraindicated in individuals with known hypersensitivity to dexketoprofen or any other NSAID, active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and in patients with a history of asthma triggered by NSAIDs. It should also be avoided in patients with uncontrolled hypertension or recent cardiovascular events unless specifically directed by a physician.